(MENAFNEditorial)
Our updated forecasts for Slovenia's pharmaceutical and healthcare expenditure indicate a rebound this year from a decline trend that was seen over the past three years. Admittedly this is true in local currency terms while the value in USD is expected to take a significant hit especially in pharmaceutical sales.
Headline Expenditure Projections
* Pharmaceuticals: EUR704mn (USD943mn) in 2014 to EUR714mn (USD893mn) in 2015; 1.5% in local currency terms and -5.4% in US dollar terms. Forecast unchanged from previous quarter.
* Healthcare: EUR3.0bn (USD4.0bn) in 2014 to EUR3.1bn (USD3.9bn) in 2015; 3.2% in local currency terms and -3.7% in US dollar terms. Forecast unchanged from previous quarter.
BMI Risk/Reward Index
Slovenia scores 50.4 out of a total of 100 in our Pharmaceutical Risk/Reward Index for Q215 - unchanged from the previous quarter. This places the country 10th in our index of 20 countries and below the average for the region which is 51.1.
Full Report Details at
- http://www.fastmr.com/prod/957445_slovenia_pharmaceuticals_healthcare_report_q2.aspx?afid=101
Key Trends & Developments
* Krka's weak nine month financial results confirmed our earlier warning of the risk posed by Russian and Ukrainian exposure to CEE pharmaceutical companies. Given the firm's largely European exposure and the significant headwinds for the pharmaceutical sector in the region achieving a growth target of 5% in 2015 will be difficult.
* The health ministries of Slovenia Croatia and Serbia are considering the possibility of joint tenders for the procurement of medicines and medical devices according to the announcement of Director of Slovenian Health Insurance Institute Samo Fakin in October 2014. The extent of the cost savings from joint procurement has been not assessed but the procurement will attract favourable pricing from suppliers noted Fakin.
* Worsening dynamics within Russia and the CIS markets will impact pharmaceutical sector growth. Russia represented the single largest market in the region and acted as the primary driver of growth in the CIS region but...
The Slovenia Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports focusing on the growth outlook for the prescription OTC patented drugs and generics market segments.
BMI's Slovenia Pharmaceuticals & Healthcare Report provides industry professionals strategists company executives investors analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Slovenia pharmaceutical and healthcare industry.
Key Benefits
* Benchmark BMI's pharmaceutical and healthcare market forecasts for Slovenia to test other views - a key input for successful budgeting and strategic business planning in the Slovenian pharmaceutical and healthcare market.
* Target business opportunities and risks in the Slovenian pharmaceutical and healthcare sector through our reviews of latest industry trends regulatory changes and major deals projects and investments in Slovenia.
* Assess the activities strategy and market position of your competitors using our company profiles (including SWOTs KPIs and latest activity) and competitive landscape tables.
Coverage
BMI Industry ViewAn at-a-glance perspective on the latest regulatory developments key forecast indicators and major corporate developments covering the prescription OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMI’s forecast analysis and taken together with BMI’s political economic and business environment SWOTs it gives a complete overview of market climate.
BMI Industry Forecast ScenarioIndustry forecasts to end-2019 for all key indicators supported by explicit assumptions plus analysis of key downside risks to the main forecasts:
* Healthcare: Total healthcare expenditure (USDbn) healthcare expenditure (% of GDP) healthcare expenditure per capita (USD) hospital beds doctors and birth & mortality rates (all per ‘000 population).
* Pharmaceutical Market: Drug expenditure in USDbn % of GDP and per capita (USD).
* Patented Drug Market: Prescription drug sales (USDbn & % of total sales).
* Generic Drug Market: Generic product sales (USDbn) generic sales (% of total sales).
* OTC Drug Market: OTC sales (USDbn & % of total sales).
* Macroeconomic Forecasts: Nominal and real GDP % real GDP growth % private consumption growth % industrial output growth % consumer price index % GDP price deflator exports imports trade balance current account balance foreign direct investment exchange rate against USD government expenditure and external debt.
BMI’s Pharmaceuticals and Healthcare Risk Reward IndexBMI’s Risk Reward Index provides investors (both national and multinational) looking for opportunities in the region with a clear country-comparative assessment of the market’s risks and potential rewards. Each of the country markets are scored using a sophisticated model that includes more than 40 industry economic and demographic data points to provide indices of highest to lowest appeal to investors with each position explained.
Market SummaryA snapshot of key market characteristics including total size of the pharmaceuticals and healthcare segments growth drivers leading therapeutic areas and the competitive landscape
Industry DevelopmentsA focus on government healthcare reforms epidemiological trends mergers and acquisitions product launches market entries FDI activity R&D biotechnology clinical trials and supply chain issues.
Regulatory RegimeDetails of the industry regulatory framework and key legislation covering the licensing of new products/services pricing and reimbursements intellectual property taxation and advertising as well as analysis of the overall regulatory burden.
Competitive LandscapeThe competitive landscape section provides comparative company analyses and index by USD sales and % share of total sales – for the total pharmaceutical sector as well as the OTC generics and distribution sub-sectors.
Company Profiles*
About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts we provide quick and easy access to the best competitive intelligence available. Our unbiased expert staff is always available to help you find the right research to fit your requirements and your budget.
For more information about these or related research reports please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.